Piramal Pharma Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
876.83 | 59.48 | 1374.14% | 876.83 | 0% |
| P/S |
|
1.93 | 18.4 | -89.53% |
|
|
| P/BV |
|
1.98 | 8.7 | -77.29% |
|
|
| P/FCF |
|
0 | -381.81 | -100% |
|
|
| Ev/Ebitda |
|
0 | 4.22 | -100% |
|
|
| Ev/S |
|
2.45 | 14.52 | -83.16% |
|
|
| Ev/FCF |
|
67.79 | -314.48 | -121.55% |
|
|
| E/P |
|
0 | 0.0159 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -32.76 | -100% | 0 | 0% |
| ROE |
|
0.2427 | 3.58 | -93.22% |
|
|
| ROA |
|
0.1195 | 3.38 | -96.47% |
|
|
| ROIC |
|
0 | 11.26 | -100% |
|
|
| ROS |
|
0.2198 | -47.93 | -100.46% |
|
|
| ROCE |
|
0 | -3.43 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0 | -0.571 | -100% | 0 | 0% |
| Nеt Debt/Ebitda |
|
0 | -0.2949 | -100% |
|
|
| Debt/Ratio |
|
0.2977 | 0.1259 | 136.41% |
|
|
| Debt/Equity |
|
0 | 0.3034 | -100% |
|
|
| Debt/Net Income |
|
255.83 | 1.67 | 15174.45% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0.18/10
|
0.0704 | 0.6379 | -88.96% | 0.0704 | 0% |
| Number of years of dividend growth |
|
0 | 0.84 | -100% | ||
| DSI |
|
1 | 0.8171 | 22.38% |
|
|
| Average dividend growth |
|
0 | 0.8603 | -100% |
|
|
| Average percentage for 5 years |
|
0.0704 | 0.8744 | -91.95% |
|
|
| Average percentage for payments |
|
11.02 | 22.22 | -50.38% |
|
|
| Difference from average difference in sector |
|
-0.5675 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
179.56 | 72.61 | 147.29% | ||
| Growth impulse Ebitda in 5 years |
|
0 | 72.97 | -100% | ||
| Growth impulse Net Income in 5 years |
|
-96.88 | 159.06 | -160.91% | ||
| Growth impulse FCF in 5 years |
|
-1350.53 | 85.72 | -1675.51% | ||
| Growth impulse EPS in 5 years |
|
-97.12 | 36.2 | -368.29% |
IP Score
3.24/10
